ALLR · Allarity Therapeutics, Inc.

This 8-K discloses no financial results, executive changes, or material agreements, but conveys meaningful clinical and strategic momentum. The presentation at Precision Medicine Forum Europe serves as a high-profile platform to communicate stenoparib’s differentiated mechanism — dual inhibition of PARP and tankyrase — and the clinical validation of its DRP® companion diagnostic, which has demonstrated predictive power in prior studies (e.g., DRP score >80 associated with 24-month median OS in ovarian cancer). The filing confirms two actively enrolling Phase 2 trials: one evaluating stenoparib monotherapy in platinum-resistant or ineligible ovarian cancer under an amended protocol designed to inform pivotal development, and another assessing stenoparib combined with temozolomide in relapsed SCLC across VA sites. These trials represent critical near-term catalysts for clinical data readouts and potential regulatory pathway definition. While the document contains forward-looking statements about safety, efficacy, and biomarker utility, all disclosed metrics — including the 22-month median OS and DRP stratification — are explicitly stated as derived from ongoing studies and presented at AACR 2026. No earnings, financing, governance, or operational updates are provided; the materiality is medium due to the absence of definitive outcomes or binding commitments, but presence of concrete trial status, biomarker validation, and external scientific engagement.